Serum proteomic patterns as a predictor of severity in acute pancreatitis

Pancreatology

Volumn 7, Issue 4, 2007, Pages 317-324

  Papachristou, Georgios I ^a   Malehorn, David E ^a   Lamb, Janette ^a   Slivka, Adam ^a   Bigbee, William L ^a   Whitcomb, David C ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Biomarkers; Pancreatitis, acute; Pathology, organ specific; Serum proteomic pattern

Indexed keywords

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEOMICS; RANK SUM TEST; STATISTICAL SIGNIFICANCE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 34748869605     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000105497     Document Type: Article

References (21)

1. Papachristou GI, Whitcomb DC: Predictors of severity and necrosis in acute pancreatitis. Gastroenterol Clin North Am 2004;33:871-890.
2. Papachristou GI, Sass DA, Avula H, Lamb J, Lokshin A, Barmada MM, Slivka A, Whitcomb DC: Is the monocyte chemotactic protein-1 -2518 g allele a risk factor for severe acute pancreatitis? Clin Gastroenterol Hepatol 2005;3:475-481.
3. Neoptolemos JP, Raraty M, Finch M, et al: Acute pancreatitis: the substantial human and financial costs. Gut 1998;42:886-891.
4. Ranson JHC, Rifkind KM, Roses DF, et al: Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet 1974;139:69-81.
5. Imrie CW, Benjamin IS, Ferguson JC, et al: A single-center double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978;65:337-341.
6. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
7. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA: Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1:683-695.
8. Wright GL Jr: SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002;2:549-563.
9. Miyamae T, Malehorn DE, Lemster B, Mori M, Imagawa T, Yokota S, Bigbee WL, Welsh MJ, Klarskov K, Nishomoto N, Vallejo AN, Hirsch R: Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus non-response to therapy. Arthritis Res Ther 2005;7:R746-R755.
10. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-1304.
11. Laronga C, Becker S, Watson P, Gregory B, Cazares L, Lynch H, Perry RR, Wright GL Jr, Drake RR, Semmes OJ: SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers 2003;19:229-238.
12. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-577.
13. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, et al: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62: 3609-3614.
14. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, et al: Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004;84: 845-856.
15. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, Dalmasso EA, Wright GL Jr: Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61:6029-6033.
16. Semmes OJ, Feng Z, Adam B-L, et al: Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-112.
17. Adam B-L, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr: Serum protein fingerprinting coupled with a pattern matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62: 3609-3614.
18. Bradley EL: A clinically based classification system for acute pancreatitis. Arch Surg 1993;128:586-590.
19. Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK, Lau WH, Au JS, Law SC, Cheng WW, et al: Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004;10:43-52.
20. Rau B, Steinbach G, Baumgart K, Gansauge F, Grunert A, Beger HG: Serum amyloid A versus C-reactive protein in acute pancreatitis: clinical value of an alternative acute-phase reactant. Crit Care Med 2000;28:736-742.
21. Mayer JM, Raraty M, Slavin J, Kemppainen E, Fitzpatrick J, Hietaranta A, Puolakkainen P, Beger HG, Neoptolemos JP: Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis. Br J Surg 2002;89:163-171.